By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Osmotica Pharmaceutical 

1205 Culbreth Drive
Suite 200
Wilmington  North Carolina  28405  U.S.A.
Phone: 910-509-0114 Fax: 910-509-0115



Company News
Osmotica Pharmaceutical Announces Its Second Late Stage NDA Asset, OS-320 (“Osmolex ER”), Has Been Awarded Orphan Drug Status By The United States FDA 7/22/2015 10:13:37 AM
Advancements In Osmotica Pharmaceutical’s CNS Pipeline For Spasticity In MS Patients And LID In Parkinson’s Patients 7/8/2015 8:16:17 AM
Osmotica Pharmaceutical Announces the Commercial Launch of Its KHEDEZLA (desvenlafaxine) Extended-Release Tablets, 50 mg and 100 mg 9/27/2013 9:34:19 AM
Osmotica Pharmaceutical Appoints Praveen Tyle, Ph.D. as President and CEO 1/4/2013 7:07:32 AM
Osmotica Pharmaceutical Announces Initiation of Phase III Studies With Arbaclofen ER Tablets 12/10/2012 9:41:50 AM
Osmotica Pharmaceutical Announces the Appointment of Praveen Tyle, PhD as Executive Vice President and Chief Scientific Officer 10/15/2012 10:17:24 AM
Osmotica Pharmaceutical and Panacea Biotech Ltd. Announce Strategic Alliance Agreement 9/11/2012 10:15:30 AM
Osmotica Pharmaceutical Announces the Appointment of Darren Alkins as Executive Vice President 9/10/2012 9:34:04 AM
Osmotica Pharmaceutical to Create 156 Jobs in Georgia 8/12/2011 7:39:36 AM
Osmotica Pharmaceutical and Upstate Pharma, LLC, a Subsidiary of UCB, Inc. (UCBJF.PK), Announce the Availability of Venlafaxine Extended-Release Tablets 10/9/2008 11:08:15 AM